The gut microbiota and inflammatory bowel diseases

Translational Research

Volumn 179, Issue , 2017, Pages 38-48

  Miyoshi, Jun ^a   Chang, Eugene B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; DYSBIOSIS; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; HEREDITY; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; ENVIRONMENT; GENETIC PREDISPOSITION; GENETICS; MICROBIOLOGY;

ANIMALS; DYSBIOSIS; ENVIRONMENT; GASTROINTESTINAL MICROBIOME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84977085549     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.06.002     Document Type: Review

References (106)

1. 1 Kaplan, G.G., The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 12 (2015), 720–727.
2. 2 Kirsner, J.B., Historical aspects of inflammatory bowel disease. J Clin Gastroenterol 10 (1988), 286–297.
3. 3 Seksik, P., Rigottier-Gois, L., Gramet, G., et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52 (2003), 237–242.
4. 4 Ott, S.J., Musfeldt, M., Wenderoth, D.F., et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53 (2004), 685–693.
5. 5 Manichanh, C., Rigottier-Gois, L., Bonnaud, E., et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55 (2006), 205–211.
6. 6 Gophna, U., Sommerfeld, K., Gophna, S., Doolittle, W.F., Veldhuyzen van Zanten, S.J., Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol 44 (2006), 4136–4141.
7. 7 Frank, D.N., St Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N., Pace, N.R., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104 (2007), 13780–13785.
8. 8 Liu, J.Z., van Sommeren, S., Huang, H., et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 47 (2015), 979–986.
9. 9 Liu, T.C., Stappenbeck, T.S., Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol 11 (2016), 127–148.
10. 10 Van Limbergen, J., Radford-Smith, G., Satsangi, J., Advances in IBD genetics. Nat Rev Gastroenterol Hepatol 11 (2014), 372–385.
11. 11 Jostins, L., Ripke, S., Weersma, R.K., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (2012), 119–124.
12. 12 Anderson, C.A., Boucher, G., Lees, C.W., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43 (2011), 246–252.
13. 13 Franke, A., McGovern, D.P., Barrett, J.C., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 42 (2010), 1118–1125.
14. 14 Ogura, Y., Bonen, D.K., Inohara, N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001), 603–606.
15. 15 Hugot, J.P., Chamaillard, M., Zouali, H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001), 599–603.
16. 16 Cadwell, K., Liu, J.Y., Brown, S.L., et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456 (2008), 259–263.
17. 17 Kaser, A., Blumberg, R.S., Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology 140 (2011), 1738–1747.
18. 18 Petnicki-Ocwieja, T., Hrncir, T., Liu, Y.J., et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A 106 (2009), 15813–15818.
19. 19 Frank, D.N., Robertson, C.E., Hamm, C.M., et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 17 (2011), 179–184.
20. 20 Knights, D., Silverberg, M.S., Weersma, R.K., et al. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med, 6, 2014, 107.
21. 21 Quince, C., Lundin, E.E., Andreasson, A.N., et al. The impact of Crohn's disease genes on healthy human gut microbiota: a pilot study. Gut 62 (2013), 952–954.
22. 22 Uhlig, H.H., Schwerd, T., Koletzko, S., et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 147 (2014), 990–1007.e3.
23. 23 Glocker, E.O., Kotlarz, D., Boztug, K., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361 (2009), 2033–2045.
24. 24 Shah, N., Kammermeier, J., Elawad, M., Glocker, E.O., Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr Allergy Asthma Rep 12 (2012), 373–379.
25. 25 Kotlarz, D., Beier, R., Murugan, D., et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 143 (2012), 347–355.
26. 26 Dhillon, S.S., Fattouh, R., Elkadri, A., et al. Variants in nicotinamide adenine dinucleotide phosphate oxidase complex components determine susceptibility to very early onset inflammatory bowel disease. Gastroenterology 147 (2014), 680–689.e2.
27. 27 Avitzur, Y., Guo, C., Mastropaolo, L.A., et al. Mutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease. Gastroenterology 146 (2014), 1028–1039.
28. 28 Orholm, M., Binder, V., Sorensen, T.I., Rasmussen, L.P., Kyvik, K.O., Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 35 (2000), 1075–1081.
29. 29 Halfvarson, J., Bodin, L., Tysk, C., Lindberg, E., Jarnerot, G., Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124 (2003), 1767–1773.
30. 30 Spehlmann, M.E., Begun, A.Z., Burghardt, J., Lepage, P., Raedler, A., Schreiber, S., Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis 14 (2008), 968–976.
31. 31 Prescott, N.J., Fisher, S.A., Franke, A., et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology 132 (2007), 1665–1671.
32. 32 Cadwell, K., Patel, K.K., Maloney, N.S., et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 141 (2010), 1135–1145.
33. 33 Molodecky, N.A., Soon, I.S., Rabi, D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.e42 quiz e30.
34. 34 Hviid, A., Svanstrom, H., Frisch, M., Antibiotic use and inflammatory bowel diseases in childhood. Gut 60 (2011), 49–54.
35. 35 Virta, L., Auvinen, A., Helenius, H., Huovinen, P., Kolho, K.L., Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease—a nationwide, register-based finnish case-control study. Am J Epidemiol 175 (2012), 775–784.
36. 36 Kronman, M.P., Zaoutis, T.E., Haynes, K., Feng, R., Coffin, S.E., Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics 130 (2012), e794–e803.
37. 37 Ungaro, R., Bernstein, C.N., Gearry, R., et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 109 (2014), 1728–1738.
38. 38 Benchimol, E.I., Mack, D.R., Guttmann, A., et al. Inflammatory bowel disease in immigrants to Canada and their children: a population-based cohort study. Am J Gastroenterol 110 (2015), 553–563.
39. 39 Bager, P., Simonsen, J., Nielsen, N.M., Frisch, M., Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis 18 (2012), 857–862.
40. 40 Cho, I., Yamanishi, S., Cox, L., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488 (2012), 621–626.
41. 41 Cox, L.M., Yamanishi, S., Sohn, J., et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158 (2014), 705–721.
42. 42 Deshmukh, H.S., Liu, Y., Menkiti, O.R., et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med 20 (2014), 524–530.
43. 43 Maurice, C.F., Haiser, H.J., Turnbaugh, P.J., Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152 (2013), 39–50.
44. 44 Wu, G.D., Chen, J., Hoffmann, C., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334 (2011), 105–108.
45. 45 De Filippo, C., Cavalieri, D., Di Paola, M., et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 107 (2010), 14691–14696.
46. 46 Devkota, S., Wang, Y., Musch, M.W., et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 487 (2012), 104–108.
47. 47 David, L.A., Maurice, C.F., Carmody, R.N., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505 (2014), 559–563.
48. 48 Wills-Karp, M., Santeliz, J., Karp, C.L., The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 1 (2001), 69–75.
49. 49 Pugazhendhi, S., Sahu, M.K., Subramanian, V., Pulimood, A., Ramakrishna, B.S., Environmental factors associated with Crohn's disease in India. Indian J Gastroenterol 30 (2011), 264–269.
50. 50 Chung, H., Pamp, S.J., Hill, J.A., et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 149 (2012), 1578–1593.
51. 51 Gomez de Aguero, M., Ganal-Vonarburg, S.C., Fuhrer, T., et al. The maternal microbiota drives early postnatal innate immune development. Science 351 (2016), 1296–1302.
52. 52 Sokol, H., Pigneur, B., Watterlot, L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105 (2008), 16731–16736.
53. 53 Sokol, H., Seksik, P., Furet, J.P., et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15 (2009), 1183–1189.
54. 54 Machiels, K., Joossens, M., Sabino, J., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63 (2014), 1275–1283.
55. 55 Gevers, D., Kugathasan, S., Denson, L.A., et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15 (2014), 382–392.
56. 56 Gu, S., Chen, D., Zhang, J.N., et al. Bacterial community mapping of the mouse gastrointestinal tract. PLoS One, 8, 2013, e74957.
57. 57 Peterson, D.A., Frank, D.N., Pace, N.R., Gordon, J.I., Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 3 (2008), 417–427.
58. 58 Schloss, P.D., Westcott, S.L., Assessing and improving methods used in operational taxonomic unit-based approaches for 16S rRNA gene sequence analysis. Appl Environ Microbiol 77 (2011), 3219–3226.
59. 59 Eren, A.M., Maignien, L., Sul, W.J., et al. Oligotyping: differentiating between closely related microbial taxa using 16S rRNA gene data. Methods Ecol Evol, 4, 2013.
60. 60 Eren, A.M., Morrison, H.G., Lescault, P.J., Reveillaud, J., Vineis, J.H., Sogin, M.L., Minimum entropy decomposition: unsupervised oligotyping for sensitive partitioning of high-throughput marker gene sequences. ISME J 9 (2015), 968–979.
61. 61 Eren, A.M., Esen, O.C., Quince, C., et al. Anvi'o: an advanced analysis and visualization platform for 'omics data. Peer J, 3, 2015, e1319.
62. 62 Wang, W., Jovel, J., Halloran, B., et al. Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria. Inflamm Bowel Dis 21 (2015), 1419–1427.
63. 63 Lepage, P., Colombet, J., Marteau, P., Sime-Ngando, T., Dore, J., Leclerc, M., Dysbiosis in inflammatory bowel disease: a role for bacteriophages?. Gut 57 (2008), 424–425.
64. 64 Perez-Brocal, V., Garcia-Lopez, R., Vazquez-Castellanos, J.F., et al. Study of the viral and microbial communities associated with Crohn's disease: a metagenomic approach. Clin Transl Gastroenterol, 4, 2013, e36.
65. 65 Iliev, I.D., Funari, V.A., Taylor, K.D., et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336 (2012), 1314–1317.
66. 66 Ott, S.J., Kuhbacher, T., Musfeldt, M., et al. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol 43 (2008), 831–841.
67. 67 Li, Q., Wang, C., Tang, C., He, Q., Li, N., Li, J., Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease. J Clin Gastroenterol 48 (2014), 513–523.
68. 68 Chehoud, C., Albenberg, L.G., Judge, C., et al. Fungal signature in the gut microbiota of pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 1948–1956.
69. 69 Lewis, J.D., Chen, E.Z., Baldassano, R.N., et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell Host Microbe 18 (2015), 489–500.
70. 70 Standaert-Vitse, A., Jouault, T., Vandewalle, P., et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn's disease. Gastroenterology 130 (2006), 1764–1775.
71. 71 Standaert-Vitse, A., Sendid, B., Joossens, M., et al. Candida albicans colonization and ASCA in familial Crohn's disease. Am J Gastroenterol 104 (2009), 1745–1753.
72. 72 Scanlan, P.D., Shanahan, F., Marchesi, J.R., Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol, 8, 2008, 79.
73. 73 Mazmanian, S.K., Round, J.L., Kasper, D.L., A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453 (2008), 620–625.
74. 74 Fujiya, M., Musch, M.W., Nakagawa, Y., et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 1 (2007), 299–308.
75. 75 Petrof, E.O., Kojima, K., Ropeleski, M.J., et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 127 (2004), 1474–1487.
76. 76 Yan, F., Cao, H., Cover, T.L., et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 121 (2011), 2242–2253.
77. 77 Vital, M., Penton, C.R., Wang, Q., et al. A gene-targeted approach to investigate the intestinal butyrate-producing bacterial community. Microbiome, 1, 2013, 8.
78. 78 Maslowski, K.M., Vieira, A.T., Ng, A., et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461 (2009), 1282–1286.
79. 79 Atarashi, K., Tanoue, T., Shima, T., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331 (2011), 337–341.
80. 80 Atarashi, K., Tanoue, T., Oshima, K., et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500 (2013), 232–236.
81. 81 Smith, P.M., Howitt, M.R., Panikov, N., et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341 (2013), 569–573.
82. 82 Roediger, W.E., Moore, J., Babidge, W., Colonic sulfide in pathogenesis and treatment of ulcerative colitis. Dig Dis Sci 42 (1997), 1571–1579.
83. 83 Levine, J., Ellis, C.J., Furne, J.K., Springfield, J., Levitt, M.D., Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 93 (1998), 83–87.
84. 84 Attene-Ramos, M.S., Nava, G.M., Muellner, M.G., Wagner, E.D., Plewa, M.J., Gaskins, H.R., DNA damage and toxicogenomic analyses of hydrogen sulfide in human intestinal epithelial FHs 74 Int cells. Environ Mol Mutagen 51 (2010), 304–314.
85. 85 Babidge, W., Millard, S., Roediger, W., Sulfides impair short chain fatty acid beta-oxidation at acyl-CoA dehydrogenase level in colonocytes: implications for ulcerative colitis. Mol Cell Biochem 181 (1998), 117–124.
86. 86 De Preter, V., Arijs, I., Windey, K., et al. Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. Inflamm Bowel Dis 18 (2012), 2371–2380.
87. 87 Giaffer, M.H., Holdsworth, C.D., Duerden, B.I., The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 35 (1991), 238–243.
88. 88 Garrett, W.S., Lord, G.M., Punit, S., et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131 (2007), 33–45.
89. 89 Garrett, W.S., Gallini, C.A., Yatsunenko, T., et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8 (2010), 292–300.
90. 90 Winter, S.E., Winter, M.G., Xavier, M.N., et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339 (2013), 708–711.
91. 91 Palm, N.W., de Zoete, M.R., Cullen, T.W., et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158 (2014), 1000–1010.
92. 92 Kau, A.L., Planer, J.D., Liu, J., et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. Sci Transl Med, 7, 2015, 276ra24.
93. 93 Moon, C., Baldridge, M.T., Wallace, M.A., Burnham, C.A., Virgin, H.W., Stappenbeck, T.S., Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation. Nature 521 (2015), 90–93.
94. 94 Patwa, L.G., Fan, T.J., Tchaptchet, S., et al. Chronic intestinal inflammation induces stress-response genes in commensal Escherichia coli. Gastroenterology 141 (2011), 1842–1851.e1–10.
95. 95 Iebba, V., Conte, M.P., Lepanto, M.S., et al. Microevolution in fimH gene of mucosa-associated Escherichia coli strains isolated from pediatric patients with inflammatory bowel disease. Infect Immun 80 (2012), 1408–1417.
96. 96 Dreux, N., Denizot, J., Martinez-Medina, M., et al. Point mutations in FimH adhesin of Crohn's disease-associated adherent-invasive Escherichia coli enhance intestinal inflammatory response. PLoS Pathog, 9, 2013, e1003141.
97. 97 Morgan, X.C., Tickle, T.L., Sokol, H., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol, 13, 2012, R79.
98. 98 Greenblum, S., Turnbaugh, P.J., Borenstein, E., Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A 109 (2012), 594–599.
99. 99 Smirnov, K.S., Maier, T.V., Walker, A., et al. Challenges of metabolomics in human gut microbiota research. Int J Med Microbiol, 2016 http://dx.doi.org/10.1016/j.ijmm.2016.03.006 [Epub ahead of print].
100. 100 Sands, B.E., Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 149 (2015), 1275–1285.e2.
101. 101 Shen, J., Zuo, Z.X., Mao, A.P., Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 20 (2014), 21–35.
102. 102 Bourreille, A., Cadiot, G., Le Dreau, G., et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 11 (2013), 982–987.
103. 103 Rossen, N.G., MacDonald, J.K., de Vries, E.M., et al. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol 21 (2015), 5359–5371.
104. 104 Angelberger, S., Reinisch, W., Makristathis, A., et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108 (2013), 1620–1630.
105. 105 Rossen, N.G., Fuentes, S., van der Spek, M.J., et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149 (2015), 110–118.e4.
106. 106 Chehoud, C., Dryga, A., Hwang, Y., et al. Transfer of viral communities between human individuals during fecal microbiota transplantation. MBio, 7, 2016.